Bronchopulmonary Dysplasia Treatment Market Outlook

The global bronchopulmonary dysplasia treatment market is expected to garner a market value of US$ 385.6 million in 2023 and is expected to accumulate US$ 700.2 million by registering a CAGR of 6.1% in the forecast period.

The market growth is attributed to the increasing cases of bronchopulmonary dysplasia along with the rise in premature births across the globe.

The market registered a CAGR of 5.0% in the historical period 2018 to 2022. Bronchopulmonary dysplasia is a chronic respiratory disease, which most commonly occurs in premature infants who received supplemental oxygen or mechanical ventilation. It is also called respiratory distress syndrome. In addition, bronchopulmonary dysplasia also occurs in infants who experience abnormal lung development or had a pre-birth antenatal infection.

Most infants recover from bronchopulmonary dysplasia, however, some of those have continued lung function and structure abnormalities during adolescence and adulthood. This condition causes serious complications during infancy and requires hospitalization and intensive medical care, during the first 2 years after birth.

The signs and symptoms of BPS include shallow, rapid breathing, chronic cough, shortness of breath, flaring of nostrils while breathing, and discoloration of skin owing to low blood oxygen levels. Many cases of BPD are associated with excess oxygen levels and mechanical ventilation.

The disease is caused by other conditions such as antenatal infection, maternal complications, preeclampsia, and inflammation of the fetal membranes, which affects the development of the lungs.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

What are the Challenges Faced by the Bronchopulmonary Dysplasia Treatment Industry?

Long-term side effects of drugs in certain cases are becoming a matter of concern for certain infants. This, in turn, is creating obstacles to market growth. Moreover, the high cost of treatment owing to the complex nature of the disease is another factor impeding the market growth.

Lack of awareness in developing countries leaves many infants undiagnosed. This, in turn, is increasing the death rate of infants. All these factors are derailing the progress of the bronchopulmonary dysplasia treatment sector.

Attributes Details
Bronchopulmonary Dysplasia Treatment Market CAGR (2023 to 2033) 6.1%
Bronchopulmonary Dysplasia Treatment Market Size (2023) US$ 385.6 million
Bronchopulmonary Dysplasia Treatment Market Size (2033) US$ 700.2 million

2018 to 2022 Bronchopulmonary Dysplasia Treatment Demand Analysis vs. Forecast 2023 to 2033

The global demand for bronchopulmonary dysplasia treatment is projected to increase at a CAGR of 6.1% during the forecast period, reaching a total of US$ 700.2 million in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5.0%.

The prevalence of the COVID-19 pandemic brought in the fear of bronchopulmonary dysplasia among healthcare professionals and parents. Thus, the demand for the treatment of the same increased drastically. Moreover, most healthcare facilities are preparing special units for the treatment of bronchopulmonary dysplasia.

Most end-user industries such as nursing homes and hospitals are ready with equipment that help in diagnosing and treating bronchopulmonary dysplasia. This, in turn, is favoring the growth of the market in the assessment period.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Which are Some Prominent Drivers of the Bronchopulmonary Dysplasia Treatment Industry?

According to the Airway estimates, in Europe and the United States, up to 160,000 infants are at high risk for the development of BPD collectively, each year. Government initiatives, favorable reimbursement policies, increasing prevalence of bronchopulmonary dysplasia, and a raise in cases of premature births leading to bronchopulmonary dysplasia are boosting the growth of the bronchopulmonary dysplasia treatment market over the forecast period.

Growing research and development activities by pharmaceutical companies to develop innovative treatment options for bronchopulmonary dysplasia boost the market in near future.

Companies are focusing on the development of novel treatment options for bronchopulmonary dysplasia for faster action and quick relief than the conventional dosage forms. For instance, Airway Therapeutics, LLC developed AT-100, a recombinant form of human surfactant protein, for maintaining healthy lung function in infants with bronchopulmonary dysplasia.

On the other hand, research is developing stem cell therapy for novel therapeutic modalities for attenuating BPD severity. Moreover, the first phase I clinical trial of stem cell transplantation for bronchopulmonary dysplasia is successfully conducted by proving its safety and feasibility in preterm infants.

Comparative View of the Market

Bronchopulmonary Dysplasia Treatment Market:

Attributes Bronchopulmonary Dysplasia Treatment Market
CAGR (2023 to 2033) 6.1%
Market Value (2033) US$ 700.2 million
Growth Factor Rising number of treatments
Opportunity Increasing healthcare facilities
Trends Extensive research and treatment options

Bronchoscopes Market:

Attributes Bronchoscopes Market
CAGR (2023 to 2033) 4.4%
Market Value (2033) US$ 803.30 million
Growth Factor Increasing elderly population
Opportunity Rising diseases due to changing lifestyles
Trends Shift from conventional invasive surgeries

Bronchitis Treatment Market:

Attributes Bronchitis Treatment Market
CAGR (2023 to 2033) 4.1%
Market Value (2033) US$ 5,730 million
Growth Factor Rising geriatric population
Opportunity Rising government-led initiatives
Trends Surging healthcare expenditure

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Regional Analysis

Countries Market Share (2022)
United States 35.6%
Germany 7.8%
Japan 3.0%

Technological Advancements Creating Lucrative Opportunities for the Bronchopulmonary Dysplasia Treatment Sector in North America?

North America is expected to dominate the global market for bronchopulmonary dysplasia treatment due to favorable government policies, increased awareness about bronchopulmonary dysplasia, and high treatment rates are expected to drive the growth of the market over the forecast period.

Advancements in the healthcare sector along with continuous research and development in treating bronchopulmonary dysplasia is favoring market growth, especially in the United States. Thus, due to the reasons mentioned above, North America held 41.2% market share in 2022.

Increasing Deaths of Infants Bolstering Early Diagnosis of Bronchopulmonary Dysplasia Treatment Industry in Europe?

Country United Kingdom
Market CAGR (2023 to 2033) 5.2%

Europe is witnessing a growth in the number of infants suffering from bronchopulmonary dysplasia. This is owing to the disease becoming more common in the region. In addition, most cases of bronchopulmonary dysplasia are undiagnosed, increasing the deaths of infants at an alarming rate. This has led to healthcare facilities in the region specifically paying attention to the cause of the diseases.

The strong presence of healthcare sectors in the Netherlands along with government policies working in the favor of childcare are accelerating the growth of the market. Thus, owing to the aforementioned reasons, Europe possessed 37.2% market share in 2022.

Increasing Awareness and Favorable Policies Accelerating Market Growth in Asia Pacific?

Countries Market CAGR (2023 to 2033)
China 9.1%
India 7.4%

With 73.6 million live births in Asia Pacific and a preterm rate of <32 weeks of approximately 2.2%, the demand for bronchopulmonary dysplasia treatment has grown over time. A rise in awareness toward the treatment of the disease and an increase in healthcare expenditure is expected to boost the market growth.

A large patient pool along with government programs and initiatives are the key factors influencing the market growth in Asia Pacific. Thus, Asia Pacific procured a 35% market share in 2022.

Category-Wise Insights

Effectiveness of Supplemental Oxygen Therapy a Dependable Treatment Option for Bronchopulmonary Dysplasia Treatment?

The oxygen therapy segment is expected to hold a significant share of the global market during the forecast period due to factors such as the effectiveness of drugs and more commonly used therapy.

In addition, oxygen supplement is an effective therapy with no risks involved and is safe for infants, making it a favorable option for treatment. Thus, supplemental oxygen supplement therapy held a 35.8% market share in 2022.

Availability of Different Treatments Making Hospitals a Feasible Option for Bronchopulmonary Dysplasia Treatment Industry?

Based on end-users, the global market is classified into hospitals, nursing homes, critical care units, and others. Amongst these, hospitals are expected to hold a significant share owing to the facilities and equipment they possess.

Most hospitals offer a variety of treatments for bronchopulmonary dysplasia making it feasible for immediate diagnosis and treatments. Thus, hospitals possessed a 47.5% market share in 2022.

Start-ups in the Bronchopulmonary Dysplasia Treatment Industry

Key bronchopulmonary dysplasia treatment start-ups are AyuVis, Exvastat, Altavant Sciences, Atriva Therapeutics, ReAlta Life Sciences, and Omnispirant.

  • In May 2022, AyuVis secured $1.8 Million through Small Business Innovation Research Grant to support the research of its investigational product (AVR-48) targeting the market.
  • Altavant, a key start-up in the bronchopulmonary dysplasia treatment sector, is focusing on creating small-molecule inhibitors for respiratory disorders.

Market Competition

Attention was drawn to modifying treatment regimens in accordance with the unique patient features and severity of the condition. Approaches to personalized medicine aimed to improve results and lessen treatment adverse effects. The pathophysiology of bronchopulmonary dysplasia was extensively researched, and possible treatment targets were found in large part by universities and research organizations. These findings helped to design novel therapeutic strategies and enhance patient outcomes.

  • In March 2022, Airway Therapeutics LLC announced the dosing of the first patient in the Phase 1b randomized trial AT-100 (rhSP-D) for preventative use in very preterm infants at risk for bronchopulmonary dysplasia (BPD). The clinical trial of the drug is expected to confirm the feasibility of intratracheal administrations of AT-100 and its beneficial safety and tolerability profile.
  • Chiesi Farmaceutici SpA, a key player in the bronchopulmonary dysplasia treatment industry, is focusing on research for newer treatments and effective drugs that increase recovery rate and reduce pain.

Key Players

  • Airway Therapeutics LLC
  • Chiesi Farmaceutici SpA
  • Insmed Incorporated
  • MediPost Co. Ltd.
  • Meridian Biotech Co. Ltd
  • Syntrix Biosystems Inc.
  • Martindale Pharmaceuticals
  • Takeda
  • Mallinckrodt
  • AdventHealth

Key Segments

By Drug Type:

  • Bronchodilators
  • Diuretics
  • Antibiotics
  • Steroids
  • Immunomodulators
  • Surfactant Homeostasis

By Therapy Type:

  • Nitric Oxide Therapy
  • Protein replacement therapy
  • Stem Cell Therapy
  • Supplemental Oxygen

By End User:

  • Hospitals
  • Nursing Homes
  • Critical Care Centers

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Frequently Asked Questions

What is the Growth Potential of the Market?

The market is forecast to register a CAGR of 6.1% through 2033.

What is the Projected Size of the Market by 2033?

The market is valued to reach US$ 700.2 million by 2033.

What Historical Changes Did the Market Undergo?

The global market advanced at a 5% HCAGR from 2018 to 2022.

How Big is the Bronchopulmonary Dysplasia Treatment Market?

The market to secure a valuation of US$ 385.6 million in 2023.

Which Section Can Acquire Significance by Therapy Type?

The supplemental oxygen supplement therapy sector comprises 35.8% of the market share.

Which End-user Segment to Capture a Significant Market Share?

The hospital category garners 47.5% of the market.

What Size is the Chinese Market?

China market is set to expand at a 9.1% CAGR.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033

        5.3.1. Bronchodilators

        5.3.2. Diuretics

        5.3.3. Antibiotics

        5.3.4. Steroids

        5.3.5. Immunomodulators

        5.3.6. Surfactant Homeostasis

    5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2023 to 2033

        6.3.1. Nitric Oxide Therapy

        6.3.2. Protein Replacement Therapy

        6.3.3. Stem Cell Therapy

        6.3.4. Supplemental Oxygen

    6.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Therapy Type, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        7.3.1. Hospitals

        7.3.2. Nursing Homes

        7.3.3. Critical Care Centers

    7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. South Asia and Pacific

        8.3.6. East Asia

        8.3.7. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Drug Type

        9.2.3. By Therapy Type

        9.2.4. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Type

        9.3.3. By Therapy Type

        9.3.4. By End User

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Type

        10.2.3. By Therapy Type

        10.2.4. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Type

        10.3.3. By Therapy Type

        10.3.4. By End User

    10.4. Key Takeaways

11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. UK

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Western Europe

        11.2.2. By Drug Type

        11.2.3. By Therapy Type

        11.2.4. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Type

        11.3.3. By Therapy Type

        11.3.4. By End User

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Czech Republic

            12.2.1.4. Romania

            12.2.1.5. Rest of Eastern Europe

        12.2.2. By Drug Type

        12.2.3. By Therapy Type

        12.2.4. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Type

        12.3.3. By Therapy Type

        12.3.4. By End User

    12.4. Key Takeaways

13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Bangladesh

            13.2.1.3. Australia

            13.2.1.4. New Zealand

            13.2.1.5. Rest of South Asia and Pacific

        13.2.2. By Drug Type

        13.2.3. By Therapy Type

        13.2.4. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Type

        13.3.3. By Therapy Type

        13.3.4. By End User

    13.4. Key Takeaways

14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Drug Type

        14.2.3. By Therapy Type

        14.2.4. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Type

        14.3.3. By Therapy Type

        14.3.4. By End User

    14.4. Key Takeaways

15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Drug Type

        15.2.3. By Therapy Type

        15.2.4. By End User

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Type

        15.3.3. By Therapy Type

        15.3.4. By End User

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Drug Type

            16.1.2.2. By Therapy Type

            16.1.2.3. By End User

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Drug Type

            16.2.2.2. By Therapy Type

            16.2.2.3. By End User

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Drug Type

            16.3.2.2. By Therapy Type

            16.3.2.3. By End User

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Drug Type

            16.4.2.2. By Therapy Type

            16.4.2.3. By End User

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Drug Type

            16.5.2.2. By Therapy Type

            16.5.2.3. By End User

    16.6. UK

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Drug Type

            16.6.2.2. By Therapy Type

            16.6.2.3. By End User

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Drug Type

            16.7.2.2. By Therapy Type

            16.7.2.3. By End User

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Drug Type

            16.8.2.2. By Therapy Type

            16.8.2.3. By End User

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Drug Type

            16.9.2.2. By Therapy Type

            16.9.2.3. By End User

    16.10. Poland

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Drug Type

            16.10.2.2. By Therapy Type

            16.10.2.3. By End User

    16.11. Russia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Drug Type

            16.11.2.2. By Therapy Type

            16.11.2.3. By End User

    16.12. Czech Republic

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Drug Type

            16.12.2.2. By Therapy Type

            16.12.2.3. By End User

    16.13. Romania

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Drug Type

            16.13.2.2. By Therapy Type

            16.13.2.3. By End User

    16.14. India

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Drug Type

            16.14.2.2. By Therapy Type

            16.14.2.3. By End User

    16.15. Bangladesh

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Drug Type

            16.15.2.2. By Therapy Type

            16.15.2.3. By End User

    16.16. Australia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Drug Type

            16.16.2.2. By Therapy Type

            16.16.2.3. By End User

    16.17. New Zealand

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Drug Type

            16.17.2.2. By Therapy Type

            16.17.2.3. By End User

    16.18. China

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Drug Type

            16.18.2.2. By Therapy Type

            16.18.2.3. By End User

    16.19. Japan

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Drug Type

            16.19.2.2. By Therapy Type

            16.19.2.3. By End User

    16.20. South Korea

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Drug Type

            16.20.2.2. By Therapy Type

            16.20.2.3. By End User

    16.21. GCC Countries

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Drug Type

            16.21.2.2. By Therapy Type

            16.21.2.3. By End User

    16.22. South Africa

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2022

            16.22.2.1. By Drug Type

            16.22.2.2. By Therapy Type

            16.22.2.3. By End User

    16.23. Israel

        16.23.1. Pricing Analysis

        16.23.2. Market Share Analysis, 2022

            16.23.2.1. By Drug Type

            16.23.2.2. By Therapy Type

            16.23.2.3. By End User

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Drug Type

        17.3.3. By Therapy Type

        17.3.4. By End User

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Airway Therapeutics LLC

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Chiesi Farmaceutici SpA

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Insmed Incorporated

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. MediPost Co. Ltd.

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Meridian Biotech Co. Ltd

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Syntrix Biosystems Inc.

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Martindale Pharmaceuticals

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Takeda

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Mallinckrodt

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. AdventHealth

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Bronchiectasis Therapeutic Market

September 2024

REP-GB-12126

Upcoming

Explore Healthcare Insights

View Reports
Future Market Insights

Bronchopulmonary Dysplasia Treatment Market